Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...

PRESS RELEASE AB SCIENCE REPORTS FOURTH CONSECUTIVE CASE OF RESPONSE FROM PHASE 1 DATA FOR THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA ...

The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...

Researchers discovered a promising leukemia drug breakthrough that could help patients overcome treatment resistance, ...

Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Asian patients with newly diagnosed acute myeloid leukemia (AML) may have superior overall survival (OS) outcomes compared with White patients, though further data are needed to corroborate this ...

Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while ...

Panelists discuss how venetoclax management requires standardized approaches to duration, bone marrow biopsy timing, growth factor use, and azole antifungal selection, with practices varying ...

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...

OXFORD, England, Jan. 6, 2026 /PRNewswire/ -- Dark Blue Therapeutics ("Dark Blue"), a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been ...

Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...